Fin|Tech|Bio at Canary Wharf: Synthetic vs Real World Data (RWD)

Fin|Tech|Bio at Canary Wharf: Synthetic vs Real World Data (RWD)

Following on from our hugely successful sold-out event in March, Canary Wharf Life Sciences and Level39 are excited to announce the second edition of Fin|Tech|Bio at Canary Wharf, taking place on Tuesday, 14th October, from 5:30pm - 8:00pm, at Level39, Canary Wharf.

Expect thought-provoking discussions, meaningful connections, and an opportunity to engage with the growing Canary Wharf life sciences and tech ecosystem.

Speakers

Speakers will be announced shortly and will include experts from CPRD MHRA, Genomics England, Life Arc and AxonJay.

About Fin|Tech|Bio at Canary Wharf

Fin|Tech|Bio is a collaborative event series exploring the convergence of biotech/techbio, finance and technology.

Synthetic data is rapidly transforming how sensitive and complex data is accessed, analysed and shared across sectors. In this second edition, our experts will discuss the growing role of synthetic data in life sciences and finance applications - two industries where data privacy, regulatory compliance and model robustness are paramount – and delve into the pros and cons of Real World Data vs Synthetic Data uses.

This event is ideal for:

• Founders, innovators and startups in healthtech, techbio, fintech, and AI/tech
• Investors exploring the frontier of data innovation
• Regulators, data scientists and research professionals

About Level39

Level39 is a melting pot of innovators, investors, industry experts and ambitious entrepreneurs, pioneering change across the sectors that dictate our experiences in daily life – FinTech, Cyber Security, Data & AI,GreenTech, Life Sciences and more.

Our flexible coworking, private office space and ecosystem activities provide members with access to the environment and growth opportunities they need to develop into world-leading businesses, that have a major financial and social impact.

About Canary Wharf Group Life Sciences

Canary Wharf Life Sciences is building a globally recognised life science ecosystem in East London. We are already home to over 40 life sciences and healthcare companies (from the MHRA and Genomics England through to high growth companies like Myricx, Cytospire and IMU Biosciences) and have 100k sqft of occupied CL2/CL3 laboratory and office space. We have laboratory and office space available now and will be opening One North Quay, Europe’s largest and most technically advanced commercial life science building, in Q1 2028 with Kadans Science Partner.

Canary Wharf Group is the developer of the largest urban regeneration project in Europe. We develop, manage and own interests in approximately 8 million sq ft of office space, 1.1 million sq ft of retail and over 2,200 apartments.

To find out more about the community, offices and laboratory spaces at Canary Wharf, contact us at members@level39.co and mairi.dillon@canarywharf.com